Search

The amount of biosolids increases every year, and social and environmental concerns are also rising due to heavy metals and pathogen contamination. Even though biosolids are considered as a waste material, they could be used as a precursor in several applications, especially in agriculture due to the presence of essential nutrients. Microwave assisted pyrolysis (MWAP) is a promising technology to safely manage biosolids, while producing value-added products, such as biochar, that can be used to improve soil fertility. This study examined the impact of pyrolysis temperature between 300 °C and 800 °C on the chemical and physical properties of biochar obtained from biosolids via MWAP. Preliminary phosphorus adsorption tests were carried out with the biochar produced from biosolids. This research demonstrated that pyrolysis temperature affects biochar specific surface area, ash and volatiles content, but does not impact heavily on the pH, chemical composition and crystalline phases of the resultant biochar. Biochar yield decreases as the pyrolysis temperature increases. Phosphorus adsorption capacity of biochar was approximately around 15 mg/g of biochar. Biochar resulting from MWAP is a potential candidate for land application with an important role in water and nutrient retention, due to the high surface area., (Copyright © 2017 Elsevier Ltd. All rights reserved.)

Preliminary research has suggested that in vitro dry matter disappearance (DMD) of some poor quality animal fodder materials can be improved by microwave treatment. Laboratory scale experiments revealed that dry matter percentage of Lucerne hay increased by 1.7% as microwave treatment time increased from 0 to 80 seconds. The in vitro DMD of lucerne hay increased by 14.9% during the same microwave treatment. In addition it was also demonstrated that microwave treatment significantly increased starch digestion of oats compared to the control samples. These experiments were followed up with a larger sample experiment in which 25 kg bags of Lucerne fodder were treated for 7.5, 15, 22.5 or 30 minutes in an experimental 6 kW microwave chamber. Dry matter percentage increased by 7.2% as microwave treatment time increased from 0 to 30 minutes. Microwave treatment significantly increased DMD during an in vitro digestion study; however there were no significant differences between the various microwave treatment times. The 15 minute treatment resulted in the greatest increase in dry matter disappearance (5.9%). The crude protein retained in the digestion residues increased by 19.2% as microwave treatment increased from 0 to 30 minutes. These laboratory studies were followed up with an animal response study in which a Merino sheep group being fed the microwave treated lucerne gained 8.1% of their initial body weight by the end of the trial compared to a 0.4% increase in body weight for the control group.

Sugar extraction from cane requires shredding and crushing, both of which are energy intensive activities. Cane shredders account for almost 30% of the total power requirements for the juice extraction train in a sugar mill with four mills. Shredder hammers also wear quickly during the crushing season and need to be regularly maintained or replaced. Microwave pre-treatment of other plant based materials has resulted in significant reductions in total processing energy. This paper briefly reviews the underlying structure of sugar cane and how microwave pre-treatment may interact with sugar cane. Microwave treatment reduced the strength of sugar cane samples to 20% of its untreated value. This strength reduction makes it easier to crush the cane and leads to a 320% increase in juice yield compared with untreated cane when cane samples were crushed in a press. There was also a 68% increase in Brix %, a 58% increase in total dissolved solids, a 58% reduction in diffusion time, a 39% increase in Pol%, and a 7% increase in juice purity compared with the control samples after 60 minutes of diffusion in distilled water.

Recent pharmacologic observations in vivo suggest the use of a lower starting dose (0.5-0.1 mU/minute) of oxytocin and a longer interval between dose augmentations (30-60 minutes) than previously advocated. In this study, a high-dose oxytocin protocol was used to augment nonprogressive labor in normal nulliparous women. The rate of oxytocin infusion started at 6 mU/minute and was increased by 6 mU/minute every 15 minutes to a maximum dose of 40 mU/minute. Charts were reviewed of 1080 nulliparous women for whom the principles of active management of labor were followed and delivery occurred between March 1, 1986 and December 31, 1988. Four hundred fifty-six who required oxytocin augmentation in labor were compared with 624 who did not receive oxytocin. There were no statistically significant differences in birth asphyxia or perinatal morbidity.

Epirubicin was studied in a phase I setting to find the maximum tolerated dose when given weekly for 3 of 4 weeks. Forty-one evaluable patients were treated in groups at doses increasing from 20 to 45 mg/m2. The highest dose level produced the maximum degree of myelosuppression (lowest neutrophil count, 1.9 X 10(9)/L; range, 0-3.7) recorded on Day 22. This was well-tolerated in this group of mainly pretreated patients. Nonhematologic side effects were minimal. This dose schedule allows a greater dose per unit time to be administered than other recommended schedules for epirubicin.

There has been a fourfold increase in cesarean births in Canada in the last 20 years. The two main indications are dystocia and repeat cesarean section. Of all primary cesarean sections, about half are due to dystocia. This is largely confined to nulliparous women. Work from Ireland suggests that a policy of active management of labor may reduce dystocia. This involves a uniform policy of amniotomy once a diagnosis of labor is established, followed by oxytocin augmentation if labor is nonprogressive (less than 1 cm/hr). From October 1, 1985, to December 31, 1986, this policy was carried out on 552 consecutive normal nulliparous women in spontaneous labor at greater than or equal to 37 weeks' gestation with a single fetus in vertex presentation with no fetal distress. These results were compared with a control group of 533 similar nulliparous women delivered between January 1, 1984 and March 31, 1985. The cesarean section rate dropped to 4.3% from 13% (p less than 0.005) and the forceps delivery rate dropped to 19.4% from 29% (p less than 0.005). The duration of labor greater than 12 hours dropped to 7% from 20% (p less than 0.005). There was no increase in fetal morbidity or mortality.

The appetite-stimulating (orexigenic) potential of the peripheral dopamine (DA) receptor antagonist domperidone was compared with that of the central DA antagonist pimozide in anorexic, tumor-bearing rats. DA antagonists were administered via the intraperitoneal route on Days 7-15 after the subcutaneous implantation of the Walker 256 carcinosarcoma. The doses of domperidone injected were 0.05 and 0.1 mg/kg once daily and 0.1 mg/kg twice daily. The dose of pimozide given was 0.1 mg/kg daily. While all doses of DA antagonists caused an initial drop in body weight and food intake, the body weight of pimozide-injected animals was not reduced significantly (in the early stages of drug treatment) as it was with the various doses of domperidone. There was significantly more food in the stomachs of domperidone- and pimozide-treated animals compared with those of the vehicle-treated, tumor-bearing animals at the time of sacrifice. These results indicate that short- and long-term satiety factors, in addition to gastric motility, should be considered when assessing the orexigenic potential of various drugs.

The technique of high-dose chemotherapy and bone-marrow transplantation takes advantage of any potential dose-response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity. We report our initial experience of 20 high-dose chemotherapy procedures with busulphan and cyclophosphamide as the treatment regimen. Autologous (14 patients), human leukocyte antigen-matched, sibling-allogeneic (five patients) and identical-twin (one patient) transplantations were performed in patients with leukaemias (12 patients), lymphomas (seven patients) or a germ-cell tumour (one patient). One in-hospital and one late death occurred as a result of the toxicity of high-dose chemotherapy. All evaluable patients demonstrated bone-marrow engraftment and became independent of blood transfusions. Five of six patients who were treated in partial remission or relapse obtained a complete remission. Seven patients have relapsed. Eleven patients currently are alive and disease-free and nine patients have returned to their full-time occupations. High-dose chemotherapy can be undertaken with an over-all morbidity that is similar to that which is experienced during the induction chemotherapy of acute leukaemia.

Gastric ulceration is frequently reported to occur in tumour-bearing animals and man, even when such tumours are not associated with organs of digestion. That central and peripheral dopamine (DA) containing neurones may be relevant to this phenomenon, is supported by the fact that the DA receptor antagonists domperidone (0.1 and 0.05 mg/kg) and pimozide (0.1 mg/kg) were observed to prevent gastric ulceration commonly reported in rats bearing the Walker 256 carcinosarcoma. Daily administration of these drugs prevented the formation of ulcers similar to those observed in vehicle-treated animals. These results demonstrate that DA neurone function is important in the formation of gastric ulcers in tumour-bearing animals and suggest that such compounds may be useful in cancer management.

A mother and son are reported who both developed hairy cell leukemia. The mother aged 74 presented with pancytopenia and responded well to splenectomy. Four years later her son aged 48 presented with pancytopenia; splenectomy was less effective but he improved after treatment with interferon-alpha. Histological examination of the splenic tissue in both cases showed changes characteristic of hairy cell leukemia. This is the third report of this rare disease occurring in family members.

A patient diagnosed as having acute lymphoblastic leukemia (L2) relapsed 4 months later and was found to have morphologic and immunologic evidence of a biphenotypic hybrid acute leukemia. Chromosome analysis at relapse showed two abnormal clones, one with marked hypodiploidy and the other with exactly double the hypodiploid clone. It is considered that this is an example of a hybrid lymphoblastic/nonlymphoblastic leukemia with unique karyotype.

Three patients with drug-induced hypoplastic anemia terminating 2 to 6 years after presentation with erythroleukemia are described. All were treated for prolonged periods with androgen and corticosteroid and two of the patients showed apparent dependence on this therapy for optimal hematologic status. The leukemic phase was heralded by loss of this dependence and development of sideroblastic dyserythropoiesis with progression to bizarre erythroid hyperplasia and fatal cytopenia. The exact relationship between androgen and corticosteroid therapy and the erythroleukemia remains speculative.